BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 27752745)

  • 1. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
    Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.
    Kawai N; Maeda Y; Kudomi N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):441-50. PubMed ID: 21072512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
    Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxic volume evaluated by
    Sato J; Kitagawa Y; Watanabe S; Asaka T; Ohga N; Hirata K; Shiga T; Satoh A; Tamaki N
    Int J Oral Maxillofac Surg; 2018 May; 47(5):553-560. PubMed ID: 29030021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
    Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of
    Okamoto M; Yamaguchi S; Sawaya R; Echizenya S; Ishi Y; Kaneko S; Motegi H; Toyonaga T; Hirata K; Fujimura M
    Biomed Res Int; 2024; 2024():2973407. PubMed ID: 38449509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
    Hirata K; Terasaka S; Shiga T; Hattori N; Magota K; Kobayashi H; Yamaguchi S; Houkin K; Tanaka S; Kuge Y; Tamaki N
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):760-70. PubMed ID: 22307533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
    Tralins KS; Douglas JG; Stelzer KJ; Mankoff DA; Silbergeld DL; Rostomily RC; Hummel S; Scharnhorst J; Krohn KA; Spence AM
    J Nucl Med; 2002 Dec; 43(12):1667-73. PubMed ID: 12468518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
    Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
    Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.
    Swanson KR; Chakraborty G; Wang CH; Rockne R; Harpold HL; Muzi M; Adamsen TC; Krohn KA; Spence AM
    J Nucl Med; 2009 Jan; 50(1):36-44. PubMed ID: 19091885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
    Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
    Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
    Cher LM; Murone C; Lawrentschuk N; Ramdave S; Papenfuss A; Hannah A; O'Keefe GJ; Sachinidis JI; Berlangieri SU; Fabinyi G; Scott AM
    J Nucl Med; 2006 Mar; 47(3):410-8. PubMed ID: 16513609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
    Rajendran JG; Mankoff DA; O'Sullivan F; Peterson LM; Schwartz DL; Conrad EU; Spence AM; Muzi M; Farwell DG; Krohn KA
    Clin Cancer Res; 2004 Apr; 10(7):2245-52. PubMed ID: 15073099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
    Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
    J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular hypoxia measured by
    Asano A; Ueda S; Kuji I; Yamane T; Takeuchi H; Hirokawa E; Sugitani I; Shimada H; Hasebe T; Osaki A; Saeki T
    Breast Cancer Res; 2018 Jul; 20(1):78. PubMed ID: 30053906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse.
    Leimgruber A; Hickson K; Lee ST; Gan HK; Cher LM; Sachinidis JI; O'Keefe GJ; Scott AM
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1476-1485. PubMed ID: 32025750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
    Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
    Kroenke M; Hirata K; Gafita A; Watanabe S; Okamoto S; Magota K; Shiga T; Kuge Y; Tamaki N
    PLoS One; 2019; 14(2):e0213111. PubMed ID: 30818360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.